This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Dermatology
  • /
  • Short- and long-term safety outcomes with ixekizum...

Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data.

Read time: 1 mins
Published:1st Mar 2017
Author: Strober B, Leonardi C, Papp KA, Mrowietz U, Ohtsuki M, Bissonnette R, et al.
Availability: Free full text
Ref.:J Am Acad Dermatol. 2017 Mar;76(3):432-440.e17.

BACKGROUND: Safety of biologics is important when treating patients with psoriasis.

OBJECTIVE: We sought to determine the safety of ixekizumab in psoriasis.

METHODS: Integrated safety data are presented from a 12-week induction period, a 12- to 60-week maintenance period, and from all ixekizumab-treated patients from 7 clinical trials. Exposure-adjusted incidence rates (IRs) per 100 patient-years are reported.

RESULTS: Overall, 4209 patients received ixekizumab (total exposure: 6480 patient-years). During the induction period, the IRs of patients experiencing 1 or more treatment-emergent adverse event (AE) were 251 and 236 among ixekizumab- and etanercept-treated patients, respectively, and for serious AEs was 8.3 in both groups. During maintenance, for ixekizumab, the IRs of treatment-emergent AEs and serious AEs were 100.4 and 7.8, respectively. Among all ixekizumab-treated patients from 7 trials, the IR of Candida infections was 2.5. The IRs of treatment-emergent AEs of special interest (including serious infections, malignancies, major adverse cardiovascular events) were comparable for ixekizumab and etanercept during the induction period.

LIMITATIONS: Additional long-term data are required.

CONCLUSION: Ixekizumab had an acceptable safety profile with no unexpected safety findings during ixekizumab maintenance in psoriasis.

Read abstract on library site

Access full article